Background: Atopic dermatitis (AD) is one of the most prevalent skin diseases, but there are numerous knowledge gaps surrounding the impact this disease has on quality of life (QoL), mental health, and out-of-pocket expenses involved in the management of AD. The available scientific evidence on the multidimensional burden of AD is usually based on studies with measures reported by patients themselves.
Methods: In this context, the MEASURE-AD trial was developed as a cross-sectional, multicenter, multinational trial using patient- and physician-reported measures to characterize the multidimensional burden of AD in adults with moderate-to-severe AD.
Results: This paper presents the results of the Spanish cohort. We found that Spanish adults with moderate-to-severe AD and high EASI score (21.1-72) had a significantly increased disease burden, high severity of symptoms such as itch and sleep disturbances, impaired mental health and QoL, higher use of health care resources, and more out-of-pocket expenses than patients with low EASI scores (0-7 or 7.1-21).
Conclusions: This study provides information to better understand disease burden, and identify aspects to be improved in the management of AD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ad.2024.04.022 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Chinese Herbal Medicine and Their Active Ingredients Involved in the Treatment of Atopic Dermatitis Related Signaling Pathways.
Phytother Res
January 2025
School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou, China.
Atopic dermatitis (AD) is a common inflammatory dermatitis of the skin and poses therapeutic challenges due to the adverse reactions and high costs associated with available treatments. In Eastern Asian countries, a plethora of herbal remedies is extensively employed for the alleviation of AD. Many of these botanicals are renowned for their formidable anti-inflammatory properties, contributing to AD management.
View Article and Find Full Text PDFEugene Hertoghe (1860-1928): Pioneer in endocrinology and the treatment of hypothyroidism.
J Med Biogr
January 2025
Department of Medicine, University of Central Florida College of Medicine, Orlando, FL, USA.
Eugène Hertoghe (1860-1928), a Belgian internist and former vice-president of the Royal Academy of Medicine of Belgium, made significant contributions to the understanding and treatment of chronic hypothyroidism. He provided a detailed clinical description of the condition, emphasizing its multisystemic manifestations and hereditary aspects. Hertoghe also documented the therapeutic use of thyroid extract, reporting its effectiveness in alleviating symptoms of hypothyroidism.
View Article and Find Full Text PDFThe stress-induced keratin intermediate filament gene/protein (K16) is spatially restricted to the suprabasal compartment of the epidermis and extensively used as a biomarker for psoriasis, hidradenitis suppurativa, atopic dermatitis and other inflammatory disorders. However, its role in these conditions remains poorly defined. Here we show that K16 negatively regulates type-I interferon (IFN) signaling and innate immune responses.
View Article and Find Full Text PDFProjected Epidemiology of Atopic Dermatitis in Children From 2022 to 2050: Findings From the Global Burden of Disease Study 2021.
Clin Exp Allergy
January 2025
National Clinical Research Center for Child Health and Disorders, Department of Dermatology, Children's Hospital of Chongqing Medical University, Ministry of Education Key Laboratory of Child Development and Disorders, Chongqing, China.
A real-world study to assess the disease control of moderate to severe atopic dermatitis in patients receiving dupilumab therapy, with atopic dermatitis control tool in Gulf countries.
J Dermatolog Treat
December 2025
Sanofi-Evidence Generation and Dissemination Manager Greater Gulf, UAE.
Purpose/aim Of The Study: There is limited real-world evidence regarding the effectiveness and safety of dupilumab in Gulf countries. The study aimed to evaluate atopic dermatitis (AD) disease control in adult and adolescent patients (≥12 years) treated with dupilumab in Gulf countries.
Materials And Methods: This observational study included patients with moderate-to-severe AD who initiated dupilumab within 30 days.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!